$MRNAModerna, Inc.

📅 Upcoming

🕒 Recent(90d)

News

• STAT+: Up and down the ladder: The latest comings and goings
  From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.
  stat · 3h ago
• STAT+: Pharmalittle: We’re reading about a big Roche investment in the U.S., estrogen patch shortages, and more
  Roche's Genentech will invest $750 million to double the size of its existing production facility in Oregon
  stat · 3h ago
• STAT+: FDA approves Ultragenyx gene therapy
  Regeneron wins ultra-rare disease drug approval, a validating win for mRNA research, and more biotech news from The Readout
  stat · 1d ago
• Contrasting legal decisions on gender-affirming care
  Heidi Overton's rise under Trump, inside a 5-year-old brain organoid, and other health news from Morning Rounds
  stat · 1d ago
• STAT+: Pharmalittle: We’re reading about a Regeneron rare disease drug, an Ultragenyx gene therapy, and more
  A Regeneron drug for an ultra-rare disease that causes bone to grow where it shouldn't won U.S. regulatory approval, capping a three-decade effort
  stat · 1d ago
• Merck’s Moderna-partnered vaccine success clears view of post-Keytruda future
  Investors had been pessimistic about the probability of success for the personalized cancer vaccine intismeran autogene, so the Phase 3 win was a welcome surprise.
  biospace · 1d ago
• STAT+: One of the most consequential years for cancer treatment, ever
  Between success with a pancreatic cancer drug and now success with an mRNA neoantigen vaccine, it has been a banner year for developing cancer therapies.
  stat · 1d ago
• Merck-Moderna cancer vaccine win spurs stock jump, speculation of Keytruda-like impact
  As the dust settles on phase 3 data that added $45 billion to Moderna’s market cap, analysts have begun to ask a question that could define cancer care in the coming years: Can use of the vaccine b…
  fiercebiotech · 1d ago
• Opinion: Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
  “Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.
  stat · 1d ago
• 7 biopharma M&A deals where layoffs followed
  Workforce cuts this year at seven companies involved in recent mergers and acquisitions will cost over 1,300 employees their jobs. Affected businesses include Arcellx and Tourmaline Bio, acquired b…
  biospace · 1d ago